Literature DB >> 2146214

CD45 molecule cross-linking inhibits natural killer cell-mediated lysis independently of lytic triggering.

G C Starling1, D N Hart.   

Abstract

The fact that certain CD45 [anti-leucocyte common antigen (LCA)] monoclonal antibodies (mAb) inhibit natural killer (NK) cell non-major histocompatibility complex (MHC)-restricted cytolysis led to the suggestion that these mAb block a 'trigger' for NK cell lytic activity. However, the discovery that the intracytoplasmic portion of the leucocyte common molecule has protein tyrosine phosphatase activity raises the possibility that the mAb initiate a direct inhibitory signal, independent of the triggering apparatus. To clarify this, we have tested the ability of CD45 antibodies to trigger NK cells and redirect cytotoxicity against mAb-producing hybridoma cells and autologous monocytes, an approach which has identified other cytotoxic trigger molecules. Peripheral blood NK cells failed to kill the CD45 antibody-producing hybridomas, although a CD3 antibody expressing hybridoma was susceptible to cytotoxic T-cell lysis. Furthermore, the CD45 mAb CMRF-12 + 26, 13.3 and HuLyM4 did not redirect lysis of autologous monocytes by NK cells, whereas the isotype-matched CD16 mAb did so. Bivalent CD45 antibody was necessary to block NK lysis of K562, as F(ab')2 but not F(ab') fragments of CMRF-12 + 26 antibody inhibited killing. Capping of the LCA appeared to correlate with the ability of the CD45 mAb to block killing, suggesting that cross-linking of LCA molecular isoforms on the NK cell surface is required for CD45 mAb to inhibit non-MHC-restricted cytolysis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146214      PMCID: PMC1384302     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Inhibition of natural killer-cell mediated cytolysis with monoclonal antibodies to restricted and non-restricted epitopes of the leucocyte common antigen.

Authors:  G C Starling; S E Davidson; J L McKenzie; D N Hart
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

2.  Poly-N-acetyllactosamine structures on murine cell surface T200 glycoprotein participate in natural killer cell binding to YAC-1 targets.

Authors:  C W Gilbert; M H Zaroukian; W J Esselman
Journal:  J Immunol       Date:  1988-04-15       Impact factor: 5.422

3.  Induction of calcium flux and enhancement of cytolytic activity in natural killer cells by cross-linking of the sheep erythrocyte binding protein (CD2) and the Fc-receptor (CD16).

Authors:  C Anasetti; P J Martin; C H June; K E Hellstrom; J A Ledbetter; P S Rabinovitch; Y Morishita; I Hellstrom; J A Hansen
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

4.  A multi-step isolation scheme for obtaining CD16+ human natural killer cells.

Authors:  L M Cosentino; M K Cathcart
Journal:  J Immunol Methods       Date:  1987-11-05       Impact factor: 2.303

Review 5.  Directed exocytosis in the NK-cell-mediated cytotoxicity. A review.

Authors:  O Carpén; E Saksela
Journal:  Nat Immun Cell Growth Regul       Date:  1988

6.  Blockade of NK cell lysis is a property of monoclonal antibodies that bind to distinct regions of T-200.

Authors:  W Newman; L D Fast; L M Rose
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

7.  Spontaneous human T-cell cytotoxicity against murine hybridomas expressing the OKT3 monoclonal antibody: comparison with natural killer cell activity.

Authors:  K Itoh; C M Balch; C D Platsoucas
Journal:  Cell Immunol       Date:  1987-09       Impact factor: 4.868

8.  Definition of a "trigger" stage in the NK cytolytic reaction sequence by a monoclonal antibody to the glycoprotein T-200.

Authors:  S R Targan; W Newman
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

9.  Inositol trisphosphate is generated by a rat natural killer cell tumor in response to target cells or to crosslinked monoclonal antibody OX-34: possible signaling role for the OX-34 determinant during activation by target cells.

Authors:  W E Seaman; E Eriksson; R Dobrow; J B Imboden
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

10.  Characterization of CD3+, CD4-, CD8- clones expressing the putative T cell receptor gamma gene product. Analysis of the activation pathways leading to interleukin 2 production and triggering of the lytic machinery.

Authors:  S Ferrini; C Bottino; R Biassoni; A Poggi; R P Sekaly; L Moretta; A Moretta
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307

View more
  5 in total

1.  Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production.

Authors:  David G T Hesslein; Rayna Takaki; Michelle L Hermiston; Arthur Weiss; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-20       Impact factor: 11.205

2.  Participation of CD45, NKR-P1A and ANK61 antigen in rat hepatic NK cell (pit cell)mediated target cell cytotoxicity.

Authors:  Dian-Zhong Luo; David Vermijlen; B lent Ahishali; Vasilis Triantis; Karin Vanderkerken; Peter JK Kuppen Kuppen; Eddie Wisse
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

3.  Morphological, phenotypic and functional characteristics of a pure population of CD56+ CD16- CD3- large granular lymphocytes generated from human duodenal mucosa.

Authors:  G Pang; A Buret; R T Batey; Q Y Chen; L Couch; A Cripps; R Clancy
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

4.  A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary natural killer cells.

Authors:  Nicholas D Huntington; Yuekang Xu; Stephen L Nutt; David M Tarlinton
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307

5.  Circulating and Tumor-Infiltrating NK Cells From Clear Cell Renal Cell Carcinoma Patients Exhibit a Predominantly Inhibitory Phenotype Characterized by Overexpression of CD85j, CD45, CD48 and PD-1.

Authors:  Andrea Ziblat; Ximena Lucía Raffo Iraolagoitia; Sol Yanel Nuñez; Nicolás Ignacio Torres; Florencia Secchiari; Jessica Mariel Sierra; Raúl Germán Spallanzani; Agustín Rovegno; Fernando Pablo Secin; Mercedes Beatriz Fuertes; Carolina Inés Domaica; Norberto Walter Zwirner
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.